Sciety and Sciety Venture Partners invest EUR 3.9 million in PeptiSystems
Sciety and Sciety Venture Partners have invested EUR 3.9 million in PeptiSystems, a biotech company developing advanced manufacturing instruments for the rapidly growing peptide and oligonucleotide therapeutics market. The funds will be used to strengthen the company's global expansion through increased production capacity, expanded sales, and further development of the product portfolio.
The market for peptide and oligonucleotide therapeutics is projected to experience substantial growth in the coming years, with some segments seeing annual growth rates of up to 20%. Across Europe, the USA, and Asia, more drug candidates targeting large patient populations are being developed using peptides and oligonucleotides. However, traditional manufacturing methods for peptides remain inefficient, creating production bottlenecks that limit patient access to new treatments.
PeptiSystems automates the production of peptides and oligonucleotides for pharmaceutical use. The company's unique flow technology, solid-phase flowthrough, reduces peptide production time from months to days and integrates real-time monitoring and data-driven process optimisation to ensure high quality and efficiency. The technology is cost-effective and sustainable, with up to 50% lower raw material consumption and carbon emissions – a solution that enables customers to streamline their production and launch drugs faster to meet growing global demand.
"Peptide and oligonucleotide therapeutics are undergoing a transformation, with more drug candidates targeting common diseases such as type 2 diabetes and cancer. This development is driving demand for more efficient production solutions. For peptides, PeptiSystems' technology is a breakthrough that resolves process bottlenecks and enables faster drug development," says Andreas Lindblom, Managing Partner at Sciety.
Since launching its products in 2021, PeptiSystems has seen strong market demand that has driven the company’s rapid revenue growth. PeptiSystems’ revenue increased from 9.8 million SEK in 2022 to 33 million SEK in 2023, and the company has built a broad customer base across major markets including the USA, China, Switzerland, Germany, France and the Netherlands.
The share issue attracted significant interest from new and existing investors, including individuals with deep industry knowledge who will actively contribute to the company's continued development.
"The fact that the company already has customers across multiple continents at an early stage confirms the potential of its solutions. The strong interest in the investment, particularly from individuals with extensive industry experience, is very positive," says Andreas Lindblom.
"The strong support from both new and existing investors is very encouraging. This capital will enable us to scale up production and advance our product portfolio to meet growing global demand. With an established customer base across the USA, Europe and Asia, we are well positioned to accelerate our growth and strengthen our market presence," says Karin Granath, CEO of PeptiSystems.
Contact
Andreas Lindblom, Managing Partner, Sciety: andreas.lindblom@sciety.se, phone +46 70-375 73 73.
Karin Granath, CEO, PeptiSystems, karin.granath@peptisystems.com, phone +46 702 82 07 47
About PeptiSystems
PeptiSystems is a biotech company offering a new generation of flow-through instruments for peptide and oligonucleotide therapeutics synthesis. Leveraging proprietary flow-through column technology, PeptiSystems' instruments significantly reduce production times, enhance synthesis control, and minimize raw material consumption while maintaining high purity and yield. With scalability in mind, these next-generation synthesis instruments seamlessly adapt from small-scale development to large-scale production, enabling pharmaceutical companies and CDMOs to meet the growing global demand for efficient, cost-effective, and sustainable manufacturing processes. PeptiSystems is headquartered in Uppsala, Sweden. For more information, visit peptisystems.com
About Sciety
Sciety is a leading investment company, committed to supporting the growth of innovative life science and health tech companies in the Nordic region. We invest alongside Sciety Venture Partners, comprising family offices and private investors, as well as venture capital firms. Our mission is to enable the full potential of life science innovations, helping to bring breakthroughs in healthcare to people all over the world. For more information, visit sciety.com
Tags:
